Description
Product details
BACLOFINE SR 30: Comprehensive Product Guide Product Overview BACLOFINE SR 30 is an advanced pharmaceutical formulation containing Baclofen 30 mg in a sustained-release delivery system. This prescription medication represents a significant advancement in the management of muscle spasticity and related neuromuscular conditions. The sustained-release technology ensures consistent therapeutic effects throughout the day, providing patients with improved symptom control and enhanced quality of life. Baclofen, the active pharmaceutical ingredient in BACLOFINE SR 30, belongs to a class of medications known as skeletal muscle relaxants and antispasmodic agents. The SR (Sustained Release) formulation is specifically engineered to release the medication gradually over an extended period, maintaining steady blood levels and reducing the frequency of dosing compared to conventional immediate-release formulations. Mechanism of Action and Therapeutic Use BACLOFINE SR 30 works by acting on the central nervous system, specifically targeting GABA-B receptors in the spinal cord and brain. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the nervous system. By stimulating these receptors, Baclofen reduces the excessive nerve signals that cause muscles to contract involuntarily, thereby alleviating spasticity and associated discomfort. The sustained-release technology incorporated in BACLOFINE SR 30 utilizes advanced polymer-based matrices that control the rate at which the active ingredient is released into the bloodstream. This innovative approach ensures that patients receive consistent therapeutic coverage for up to 12-24 hours from a single dose, eliminating the peaks and troughs associated with immediate-release formulations. Primary Indications BACLOFINE SR 30 is primarily prescribed for managing muscle spasticity associated with various neurological conditions including multiple sclerosis, spinal cord injuries, cerebral palsy, stroke, brain injuries, and other conditions affecting the central nervous system. The medication is particularly beneficial for patients experiencing painful muscle spasms, stiffness, and involuntary muscle contractions that interfere with daily activities, mobility, and rehabilitation efforts. Key Benefits of BACLOFINE SR 30 Extended Duration of Action The most significant advantage of BACLOFINE SR 30 is its sustained-release formulation, which provides prolonged therapeutic effects. Patients typically require only one or two doses per day, compared to three or four doses with conventional formulations. This extended duration improves medication adherence and provides more consistent symptom control throughout the day and night. Improved Symptom Management By maintaining steady blood levels of Baclofen, BACLOFINE SR 30 delivers superior control of muscle spasticity with fewer fluctuations in symptom relief. Patients experience reduced muscle stiffness, decreased frequency and severity of muscle spasms, improved range of motion, and enhanced ability to participate in physical therapy and rehabilitation programs. Enhanced Quality of Life The consistent therapeutic effects of BACLOFINE SR 30 translate into meaningful improvements in daily functioning. Patients often report better sleep quality due to reduced nighttime spasms, improved mobility and independence in performing daily activities, reduced pain and discomfort associated with muscle spasticity, and greater participation in social and recreational activities. Reduced Dosing Frequency The sustained-release technology means fewer doses throughout the day, which simplifies medication regimens and improves compliance, particularly for patients managing multiple medications. This convenience factor is especially valuable for individuals with cognitive impairments or those who require caregiver assistance with medication administration. Smoother Therapeutic Response Unlike immediate-release formulations that can cause pronounced peaks in drug levels, BACLOFINE SR 30 provides a more gradual and sustained therapeutic effect. This results in reduced risk of dose-related side effects, more stable muscle relaxation throughout the dosing interval, and minimized breakthrough spasticity between doses. Potential Side Effects and Considerations While BACLOFINE SR 30 is generally well-tolerated, patients should be aware of potential side effects. It's important to note that not everyone experiences these effects, and many side effects diminish as the body adjusts to the medication. Common Side Effects The most frequently reported side effects include drowsiness and sedation, which typically occur during initial therapy or dose adjustments. Patients may also experience dizziness, fatigue, weakness, headache, nausea, and constipation. These effects are usually mild to moderate and often resolve within the first few weeks of treatment. Central Nervous System Effects Some patients may experience confusion, particularly elderly individuals, difficulty concentrating, insomnia or sleep disturbances, and mood changes. These effects should be monitored and reported to healthcare providers if they persist or worsen. Cardiovascular and Other Effects Occasional side effects may include hypotension (low blood pressure), urinary frequency or retention, dry mouth, and muscle weakness beyond the intended therapeutic effect. Serious Considerations Patients should seek immediate medical attention if they experience severe allergic reactions, hallucinations or severe confusion, difficulty breathing, severe muscle weakness affecting breathing or swallowing, or signs of overdose including extreme drowsiness, respiratory depression, or seizures. Important Warnings BACLOFINE SR 30 should never be discontinued abruptly without medical supervision, as sudden withdrawal can lead to serious complications including seizures, hallucinations, increased spasticity, and other potentially life-threatening symptoms. Dose reduction must be gradual and carefully supervised by a healthcare provider. The medication may cause drowsiness and impair mental alertness, so patients should avoid driving, operating machinery, or engaging in activities requiring full alertness until they understand how the medication affects them. Alcohol and other central nervous system depressants should be avoided or used with extreme caution, as they can potentiate the sedative effects of Baclofen. Dosage and Administration Guidelines BACLOFINE SR 30 should be taken exactly as prescribed by a healthcare provider. The tablets should be swallowed whole and not crushed, chewed, or broken, as this would compromise the sustained-release mechanism and potentially lead to dose dumping. The medication can be taken with or without food, though taking it with food may help reduce gastrointestinal side effects. Dosage is highly individualized based on the patient's condition, response to treatment, and tolerance. Healthcare providers typically initiate therapy at lower doses and gradually titrate upward to achieve optimal therapeutic effects while minimizing side effects. Conclusion BACLOFINE SR 30 represents a sophisticated therapeutic option for individuals struggling with muscle spasticity and related neuromuscular conditions. The sustained-release formulation offers distinct advantages over conventional immediate-release preparations, including extended duration of action, improved symptom control, reduced dosing frequency, and enhanced patient convenience and compliance.
